allantoin has been researched along with Renal Insufficiency, Chronic in 6 studies
Renal Insufficiency, Chronic: Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pruritus is the most common skin symptom in patients with CKD, especially in end-stage renal disease." | 5.91 | Allantoin induces pruritus by activating MrgprD in chronic kidney disease. ( Dong, X; Jing, T; Jun, S; Shen, X; Sheng, M; Sun, J; Sun, Y; Tang, Z; Wang, C; Yang, Y; Yu, G; Zhu, C, 2023) |
| "Amelioration of both oxidative and inflammation status after cholesterol lowering treatment in CKD might be mediated by restoration of antioxidant taurine concentrations during therapy (from 51." | 5.20 | Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement. ( Carru, C; Mangoni, AA; Sanna, M; Satta, AE; Sotgia, S; Zinellu, A, 2015) |
| " Plasma MED concentrations, inflammation and oxidative stress indices [Kynurenine/Tryptophan (Kyn/Trp) ratio, malondialdehyde (MDA) and allantoin/uric acid (All/UA) ratio] were measured in 30 CKD patients randomized to three cholesterol lowering regimens for 12 months (simvastatin 40mg/day, ezetimibe/simvastatin 10/20mg/day, or ezetimibe/simvastatin 10/40mg/day)." | 3.83 | Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease. ( Carru, C; Ena, S; Mangoni, AA; Satta, AE; Sotgia, S; Sotgiu, E; Zinellu, A, 2016) |
| "Pruritus is the most common skin symptom in patients with CKD, especially in end-stage renal disease." | 1.91 | Allantoin induces pruritus by activating MrgprD in chronic kidney disease. ( Dong, X; Jing, T; Jun, S; Shen, X; Sheng, M; Sun, J; Sun, Y; Tang, Z; Wang, C; Yang, Y; Yu, G; Zhu, C, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, Y | 1 |
| Sun, Y | 1 |
| Zhu, C | 1 |
| Shen, X | 1 |
| Sun, J | 1 |
| Jing, T | 1 |
| Jun, S | 1 |
| Wang, C | 1 |
| Yu, G | 1 |
| Dong, X | 1 |
| Sheng, M | 1 |
| Tang, Z | 1 |
| Zinellu, A | 4 |
| Sotgia, S | 4 |
| Sotgiu, E | 2 |
| Assaretti, S | 1 |
| Baralla, A | 1 |
| Mangoni, AA | 3 |
| Satta, AE | 4 |
| Carru, C | 4 |
| Hu, JR | 1 |
| Coresh, J | 1 |
| Inker, LA | 1 |
| Levey, AS | 1 |
| Zheng, Z | 1 |
| Rebholz, CM | 1 |
| Tin, A | 1 |
| Appel, LJ | 1 |
| Chen, J | 1 |
| Sarnak, MJ | 1 |
| Grams, ME | 1 |
| Sanna, M | 1 |
| Ena, S | 1 |
| Pisanu, E | 1 |
| Loriga, G | 1 |
| Deiana, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Metabolic and Anti-Inflammatory Effects of Combined Ezetimibe and Simvastin Therapy, as Compared to Simvastatin Alone, in Patients With Chronic Proteinuric Nephropathy[NCT00861731] | Phase 4 | 30 participants (Anticipated) | Interventional | 2008-11-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for allantoin and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Cholesterol lowering treatment restores blood global DNA methylation in chronic kidney disease (CKD) patients.
Topics: 5-Methylcytosine; Aged; Allantoin; Biomarkers; Cholesterol; DNA Methylation; Down-Regulation; Ezetim | 2017 |
Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement.
Topics: Aged; Allantoin; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dose-Res | 2015 |
LDL S-homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy.
Topics: Allantoin; Apolipoproteins B; Azetidines; Cholesterol, LDL; Drug Combinations; Dyslipidemias; Ezetim | 2012 |
3 other studies available for allantoin and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Allantoin induces pruritus by activating MrgprD in chronic kidney disease.
Topics: Allantoin; Animals; Calcium; Mice; Pruritus; Receptors, G-Protein-Coupled; Renal Insufficiency, Chro | 2023 |
Serum metabolites are associated with all-cause mortality in chronic kidney disease.
Topics: Adult; Aged; Allantoin; Biomarkers; Cause of Death; Cohort Studies; Female; Follow-Up Studies; Fumar | 2018 |
Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease.
Topics: Allantoin; Anticholesteremic Agents; Arginine; Biomarkers; Cholesterol; Endothelium; Ezetimibe; Fema | 2016 |